Last updated: February 16, 2026
Executive Summary
NDC 62011-0311 is identified as Mavenclad (cladribine), a drug approved for multiple sclerosis (MS). The drug is marketed by EMD Serono and Merck KGaA. It gained approval in the US in 2019 for relapsing forms of MS, providing an oral therapeutic option with a distinct dosing regimen.
Market dynamics for Mavenclad focus on multiple sclerosis treatment, competitive positioning, and pricing strategies amid increasing demand for oral disease-modifying therapies (DMTs).
Market Overview
Indication and Therapeutic Profile
- Indication: Relapsing multiple sclerosis (RMS), including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
- Mechanism: Cladribine works as an immunosuppressant by selectively reducing lymphocytes, which decreases MS activity.
- Administration: Oral, taken in two treatment courses over two years (one tablet course annually).
Market Size and Demographics
- The global MS market was valued at approximately $22 billion in 2021 and is projected to reach $37 billion by 2027, growing at a CAGR of 8.0% (Source: MarketsandMarkets).
- The US accounts for nearly 50% of global MS revenue, with approximately 1 million MS patients nationwide.
- The relapsing MS segment dominates, representing about 70% of all MS cases.
Competitors
- Fingolimod (Gilenya)
- Dimethyl fumarate (Tecfidera)
- Ocrelizumab (Ocrevus)
- Siponimod (Mayzent)
- Other oral DMTs and infusion therapies.
Market Trends
- Increasing prescriptions of oral DMTs driven by patient preference for ease of administration.
- Greater emphasis on safety profiles; Mavenclad's notable risk of lymphopenia affects prescribing decisions.
- Payer and formulary dynamics favor drugs with favorable efficacy, safety, and convenience profiles.
Price Structure and Reimbursement
Pricing Data
- The wholesale acquisition cost (WAC) for Mavenclad in the US is approximately $86,000 for a two-year treatment course (Source: SSR Health 2022).
- Per 28-day treatment period cost: roughly $43,000.
- The list price equates to about $1,448 per 28-tablet course, considering 28 tablets per course.
Reimbursement Policy
- Covered by Medicare Part D, Medicaid, and commercial insurers.
- Cost-sharing depends on patient insurers' formulary status; rebates and discounts are common.
- High-cost drugs like Mavenclad often face tiered formulary placements, influencing patient access and out-of-pocket expenses.
Price Projections
Short-Term (Next 1-2 Years)
- Slight price stability expected due to existing patent protection and demand.
- Potential discounts due to negotiations with payers; average net price likely lower than WAC by 15-25%.
Mid to Long-Term (3-5 Years)
- Patent expiry in 2032 may lead to generic entry, causing significant price erosion.
- Entry of biosimilars or alternative oral agents could prompt competitive price reductions.
- Price decline forecast: 20-40% over five years post-patent expiry, contingent on market penetration and regulatory approvals of generics or biosimilars.
Strategic Considerations
- Enhancing safety profile management can maintain market share.
- Expansion into secondary indications or combination therapies might influence future pricing strategies.
- Market penetration will depend on formulary access, physician acceptance, and patient preference.
Regulatory and Patent Outlook
- Patent protection for Mavenclad is expected to remain until 2032, with regulatory exclusivity in the US ending around 2031.
- Pending patent challenges or extensions may influence pricing dynamics.
Summary Table
| Aspect |
Data |
| Current WAC (US) |
~$86,000 for a two-year course |
| Cost per 28-day course |
~$43,000 |
| Patient market size (US) |
~1 million MS patients |
| Market growth (global) |
Approximately 8% CAGR (2021-2027) |
| Patent expiry (US) |
2032 |
| Expected price decline |
20-40% within 5 years post-patent expiration |
Key Takeaways
- Mavenclad holds a significant share of the oral MS therapy market due to its dosing regimen and efficacy.
- Current US list prices position Mavenclad as a high-cost but competitive option, with reimbursement pressures influencing net seller revenue.
- Price erosion is anticipated following patent expiry, with biosimilar entry likely impacting market share.
FAQs
-
What is the main driver of Mavenclad's market for MS?
Its oral administration and dosing schedule appeal to patients and providers, aiding market penetration.
-
When will Mavenclad face generic competition?
Patent expiration in the US is projected for 2032, with generic entry likely following shortly after.
-
How does safety profile influence Mavenclad's pricing?
Safety concerns like lymphopenia require monitoring, which can influence prescribing and reimbursement decisions.
-
Are there any indications beyond MS for Mavenclad?
As of now, the drug is approved solely for MS treatment; expansion into other indications remains unapproved.
-
What are the main factors affecting future pricing?
Patent status, competition, regulatory changes, and payer negotiations.
Sources
- MarketsandMarkets. "Multiple Sclerosis Market." 2021.
- SSR Health. "Pricing Data for Mavenclad," 2022.
- FDA. "Mavenclad (cladribine) label." 2019.
- IQVIA. "US MS Market Insights," 2022.
- Federal Register. "Patent Status and Market Exclusivity," 2022.
